Previous close | 1.7900 |
Open | 1.8000 |
Bid | 1.6700 x 100 |
Ask | 1.7400 x 500 |
Day's range | 1.6700 - 1.8256 |
52-week range | 0.7700 - 14.0000 |
Volume | |
Avg. volume | 6,533,883 |
Market cap | 6.893M |
Beta (5Y monthly) | 1.53 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc (NASDAQ:ADIL). This patent expands Adial’s intellectual property protection and covers the combination of the company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the company’s lead investigational new drug pr
Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
Wednesday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced patent number 11,905,562 was issued on February 20, 2024, by the United States Patent and Trademark Office. The patent covers the company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder. The company says the new patent strengthens Adial’s patent portfolio and covers AD04’s ability to target the serotonin transporter gene for the p